4.5 Article Proceedings Paper

Persistence of Hypercoagulable State after Resection of Intra-Abdominal Malignancies

Journal

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
Volume 216, Issue 4, Pages 580-589

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jamcollsurg.2012.12.006

Keywords

-

Categories

Ask authors/readers for more resources

BACKGROUND: The hypercoagulable state associated with cancer imparts considerable risk for venous thromboembolism. Surgical resection of malignancies should theoretically reverse tumor-induced hypercoagulability. However, coagulation changes in cancer patients postresection have not been described thoroughly. Conventional coagulation tests are unable to detect hypercoagulable states. In contrast, rotational thromboelastography (ROTEM) can detect hypo- or hypercoagulable conditions. We hypothesized that the cancer-induced hypercoagulable state would improve after surgical resection. METHODS: After informed consent, blood samples of patients undergoing surgical resection for curative intent were analyzed with serial ROTEM. RESULTS: Thirty-five patients (mean +/- SD age 66 +/- 17 years; 67% male) had cancers involving the pancreas (n = 12 [34%]), esophagus (n = 10 [29%]), stomach (n = 7 [20%]), bile ducts (n = 3 [9%]), and duodenum (n = 3 [9%]). Preoperative ROTEM identified 14 (40%) who were hypercoagulable. After surgical resection, patients became progressively hypercoagulable with more rapid clot formation time (low clot formation time, high alpha) and higher maximum clot firmness. By week one, 86% (n = 30) had abnormal ROTEM values, including 17 of 21 (81%) who had normal coagulation profiles preoperatively. Most (n = 30 [86%]) remained hypercoagulable at 3 to 4 weeks. CONCLUSIONS: Rotational thromboelastography identifies baseline hypercoagulability in more than one third of patients with intra-abdominal malignancies. This is among the first studies to demonstrate progressive hypercoagulability that persists for at least 1 month after resection. These data support postdischarge thromboprophylaxis regimens in high-risk cancer patients. (J Am Coll Surg 2013; 216: 580-590. (C) 2013 by the American College of Surgeons)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available